Buscar
Lantheus Holdings Inc
LNTHAñadir a la lista de seguimiento
109.010USD
+4.160+3.97%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
7.09BCap. mercado
25.78P/E TTM
Más Datos de Lantheus Holdings Inc Compañía
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Información de Lantheus Holdings Inc
Símbolo de cotizaciónLNTH
Nombre de la empresaLantheus Holdings Inc
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoMarkison (Brian A)
Número de empleados808
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección331 Treble Cove Road
CiudadNORTH BILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01862
Teléfono19786718001
Sitio Webhttps://www.lantheus.com/
Símbolo de cotizaciónLNTH
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoMarkison (Brian A)
Ejecutivos de Lantheus Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
4.70K
+88.02%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Lantheus Holdings Inc?
Los cinco principales accionistas de Lantheus Holdings Inc son: Ms. Mary Anne Heino
¿Cuántas instituciones poseen acciones de Lantheus Holdings Inc (LNTH)?
A fecha de 2026Q1, 1043 instituciones poseen acciones de Lantheus Holdings Inc, con un valor de mercado combinado de aproximadamente 77.80M, lo que representa el 119.49% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5936003.00.
